MDMA-Assisted Therapy

Evidence, history, therapeutic process and lived experience

Sculptural glass forms catching golden light beside sage foliage and blossoms on sunlit stone

What is it?

MDMA, or 3,4-methylenedioxymethamphetamine, is a synthetic psychoactive substance that can temporarily alter mood, emotional processing, fear responses and feelings of connection.

Although it is often grouped with psychedelics, MDMA is not considered a classic psychedelic like psilocybin, LSD or DMT. It is commonly described as an entactogen or empathogen, meaning it can increase feelings of empathy, emotional openness, trust and connection while usually producing fewer visual or perceptual changes than classic psychedelics.

In a therapeutic setting, MDMA can help create a state where people feel more able to access difficult emotions, memories and experiences without becoming as overwhelmed by fear or defensiveness. This is one of the reasons it has attracted so much interest in the treatment of post-traumatic stress disorder, or PTSD.

At The Mental Wealth Hub, we see MDMA-assisted therapy as much more than the medicine itself. The relationship with the therapist, the environment, the preparation beforehand and the integration afterwards can all profoundly shape the experience.

A brief history of MDMA

MDMA has a history stretching back more than a century. It was first synthesised in 1912 by German chemist Anton Köllisch, who worked for the pharmaceutical company Merck. [1]

A commonly repeated story claims MDMA was created as an appetite suppressant, but historical reviews of Merck's original records found this was not the case. Köllisch synthesised MDMA while developing an alternative pathway to manufacture hydrastinine, a medicine used to help control bleeding. [1]

For decades, MDMA remained relatively obscure. That changed through the work of American chemist Alexander “Sasha” Shulgin, who revisited the compound in the 1970s and became interested in its psychological effects. Shulgin later introduced MDMA to psychotherapist Leo Zeff, who began using it as an adjunct to psychotherapy and sharing the approach with other therapists. [6]

During this period, some therapists referred to MDMA as “Adam”, believing it helped people access emotions with less fear and defensiveness and allowed them to return to a more open, emotionally connected state.

Throughout the late 1970s and early 1980s, MDMA began being explored in psychotherapy for trauma, relationships and emotional processing. Recreational use also increased significantly, and in the United States MDMA was placed into Schedule I in 1985, bringing legal therapeutic use largely to an end outside research settings. [2]

Clinical research gradually returned over the following decades, eventually leading to modern Phase 3 trials examining MDMA-assisted therapy for PTSD. More than a century after MDMA was first synthesised, Australia introduced a pathway in 2023 allowing authorised psychiatrists to prescribe MDMA for PTSD within carefully structured therapeutic programs. [5]

Its journey has been extraordinary: from an overlooked laboratory compound, to psychotherapy tool, to prohibited recreational drug, and now back into clinical treatment and mental health research.

What may it help with?

Trauma can leave the nervous system reacting to past experiences as though the danger is still happening now. For some people, traditional trauma therapy can be difficult because talking about painful experiences triggers overwhelming fear, shutdown, dissociation or emotional flooding. MDMA appears to create a different emotional environment in which those memories can sometimes be approached with greater openness and less fear.

PTSD Trauma CPTSD

How does it work?

People may feel more compassionate towards themselves, more connected to their therapist and more capable of remaining present with experiences they previously found too difficult to explore. This is what makes MDMA-assisted therapy particularly interesting for trauma. It may create a window in which someone can revisit what happened while feeling safe enough to process it differently.

For many people, that feeling of safety is central to the work.

What does the evidence say?

The strongest clinical evidence for MDMA-assisted therapy is currently in moderate to severe PTSD. Two major Phase 3 studies found substantial reductions in PTSD symptoms when MDMA was combined with structured psychotherapy. [3, 4]

In a 2023 Phase 3 trial, 86.5% of participants receiving MDMA-assisted therapy experienced a clinically meaningful improvement in PTSD symptoms, 71.2% no longer met the diagnostic criteria for PTSD at the study endpoint, and 46.2% met the study’s definition of remission. [4]

Participants also experienced improvements in day-to-day functioning, including relationships, work and social life. These results have helped make MDMA-assisted therapy one of the most closely watched developments in modern trauma treatment.

Promising results aren't the whole story, and you deserve to see the rest of it.

In August 2024, the US Food and Drug Administration declined to approve MDMA-assisted therapy for PTSD. It asked for further research on how long the benefits last, a fuller picture of safety, and stronger steps to reduce potential bias in the results. [7]

That same month, the journal Psychopharmacology retracted three earlier papers drawn from the Phase 2 trials, after finding that protocol violations at one study site had not been disclosed. The Phase 3 results described above were published separately and have not been retracted. [8, 9, 10]

In August 2026, the developer resubmitted its application to the FDA without running a new Phase 3 trial, which begins a fresh evaluation of the treatment's safety and effectiveness. [7]

None of this erases what many participants experienced. It does mean the evidence is still being tested, and it's worth holding these results with both hope and care.

Importantly, the outcomes came from a complete therapeutic process involving preparation, extended medicine sessions, trusted therapists and integration afterwards. The medicine and the therapeutic relationship work together.

What does a session or practice look like?

MDMA-assisted therapy usually begins with preparation sessions where the participant builds trust with the therapist, discusses their history, explores what they would like support with and becomes familiar with how the medicine session will work.

The medicine session itself can typically last around six to eight hours. During this time, the participant may talk extensively with the therapist, move between conversation and quiet internal reflection, revisit memories, experience emotional release or simply allow whatever needs to surface to unfold naturally.

One of the most important elements is the relationship with the therapist. The participant needs to feel genuinely comfortable, respected and emotionally safe with the person or people supporting them. Vulnerability is often a major part of these sessions, so the ability to feel seen, heard and accepted without judgement can be incredibly powerful.

The environment matters too. A nurturing setting where someone feels physically comfortable, emotionally supported and able to surrender into the process can create the conditions for deeper therapeutic work.

This is not simply about administering MDMA and waiting for something to happen. The human connection surrounding the experience can be one of its most meaningful components.

The importance of trust and vulnerability

MDMA-assisted therapy can bring people into contact with parts of themselves they may have protected, avoided or disconnected from for years. That level of vulnerability requires trust.

Someone may talk about memories they have never previously shared. They may experience grief, anger, shame, fear, love or compassion with an intensity they have not previously allowed themselves to feel.

This is why choosing a therapist who feels right is so important. Qualifications and experience matter, but so does the human connection. Do you feel comfortable with them? Do you feel they are truly listening? Do you feel emotionally safe? Do you feel you could be vulnerable without needing to perform, explain or protect yourself?

Being deeply seen and heard by another person in a safe environment can itself become part of the healing experience.

What might someone experience during a session?

Every experience is different. Some people describe increased emotional openness, compassion, trust and connection. Others revisit traumatic memories, relationships or events from their past. Some experience a new perspective on experiences they have carried for years.

People may talk throughout much of the session or move between conversation and periods of internal reflection. Unlike classic psychedelics, MDMA generally produces less visual distortion, meaning many people remain relatively clear and communicative throughout the experience.

That can make it particularly suited to therapeutic work involving conversation, memory, relationships and trauma. People often describe feeling more able to look at painful experiences without becoming completely consumed by them.

Why integration matters

The experience does not end when the medicine wears off. Insights, emotions and memories may continue unfolding in the days and weeks that follow. Integration gives people space to understand what came up, recognise patterns and begin making practical changes in their lives.

This might involve psychotherapy, somatic or body-based therapy, journalling, nervous-system work, reflection or conversations with trusted people. For trauma in particular, someone may understand something intellectually while their body still holds tension, fear or emotional activation.

Remember: the medicine may open the door, but the work afterwards helps create lasting change.

What makes a good therapeutic environment?

The therapeutic setting can have an enormous influence on the experience. A good environment should feel private, calm, nurturing and comfortable. Participants may spend many hours in the same space, so feeling physically at ease matters.

Music is often used during sessions, along with comfortable furniture, blankets, eye masks and other elements designed to help someone feel safe enough to focus inward.

But beyond the physical environment, the emotional environment matters just as much. A participant should feel supported rather than observed, heard rather than analysed, and safe enough to express whatever emerges.

For many people, the ability to experience difficult emotions while another person remains calm, present and accepting can become an important part of the healing process itself.

Risks and considerations

Physical effects can include raised heart rate and blood pressure, jaw clenching, nausea and changes in body temperature.
Emotional effects can include anxiety and low mood in the days afterwards.
Screening matters. Psychedelic treatments aren't suitable for everyone. People with a personal or family history of psychosis or bipolar disorder, some heart conditions, or who take certain medications may face serious risks. A thorough medical and psychiatric assessment is essential.
Therapy relationships need strong safeguards. People in altered states can be vulnerable. Ask how the clinic protects clients, including having more than one therapist present.
Street MDMA is very different. Illegal pills and powders often contain other substances and unknown doses, and are used without screening or support.
Access is limited and costly, and isn't covered by Medicare or the PBS.
Never take these substances without medical supervision, and never stop or change your medication without speaking to your doctor.

Is MDMA-assisted therapy the same as recreational MDMA?

No. The therapeutic experience is very different from recreational use. Clinical MDMA-assisted therapy takes place within a structured environment with known dosing, preparation beforehand, professional support throughout the session and therapeutic integration afterwards.

The purpose is also completely different. Rather than seeking stimulation or recreation, the medicine is used to support emotional processing, self-exploration and therapeutic work. The intention, environment and therapeutic relationship can dramatically change the nature of the experience.

Access in Australia

Australia introduced a pathway for therapeutic MDMA on 1 July 2023. Specialist psychiatrists can apply to become Authorised Prescribers of MDMA for the treatment of PTSD. [5]

This represented a significant shift in the recognition of psychedelic-assisted therapies in Australia and made the country one of the first in the world to establish a formal pathway for this type of treatment.

Access remains relatively limited and specialised, but the regulatory change marked an important step in bringing this work back into mainstream mental health care.

Mental Wealth Hub note: This page is designed to support informed exploration and conversation. It combines published research, current Australian context and lived experience.

Questions to ask a practitioner

When exploring MDMA-assisted therapy, the therapist and treatment environment are just as important as the medicine itself.

Qualifications and experience: Are you an authorised prescriber, or working with one? How long have you been working with psychedelic-assisted therapy, and what experience do you have working specifically with trauma?
Screening and suitability: What medical and psychological screening is included? How do you assess heart health, blood pressure, a personal or family history of psychosis or bipolar disorder, and my current medications?
Preparation: How much preparation do we do beforehand, and how will you help me feel ready?
Consent and safeguards: How do we agree on boundaries beforehand, including any physical touch? Will more than one therapist be present during the medicine session?
During the session: Who will be with me throughout the medicine session? Can I talk throughout if I want to, and how do you work with emotions or memories that surface?
Emergency procedures: What happens if I become very distressed or medically unwell? What is your emergency plan?
Therapeutic approaches: Do you offer somatic or body-based approaches? How do you create a nurturing and emotionally safe environment?
Integration and ongoing support: How many integration sessions do you recommend afterwards, and what support is available between sessions?
What does the complete program involve?

Most importantly, notice how you feel with the therapist. The right therapeutic relationship should allow you to feel increasingly safe, comfortable and able to be yourself.

Founder’s Insight

MDMA-assisted therapy was incredibly helpful for me in working through complex PTSD.

One of the things I have learnt through psychedelic-assisted therapies is that I may go into a session with one intention, but what actually surfaces is often completely different. The insights can be incredibly revealing because the experience does not necessarily take you where your conscious mind expects to go.

For me, one MDMA-assisted therapy session was not enough. After my second treatment, it genuinely felt as though a part of my brain had switched back on.

At another point in my healing I underwent three medicine-assisted sessions, similar to the three-session structure used in the MAPS clinical trials, and I personally felt I needed all three.

What was equally important was the relationship with the therapist and what happened afterwards. These sessions require real vulnerability. Feeling safe enough to surrender, speak openly and allow whatever needed to come up was incredibly important for me. Being in a nurturing environment where I felt seen, heard and supported made the experience much more powerful.

I also needed considerable integration afterwards. Even when my mind had processed something, I could still feel angst and activation held within my body. Somatic and body-based therapy became particularly important in helping me move through what remained.

MDMA-assisted therapy did not do all of the healing for me. But it helped me access emotions, memories and parts of myself that had previously been incredibly difficult to reach.

For my own complex PTSD, I found it profoundly helpful. Like several psychedelic-assisted therapies I have experienced, parts of the process were difficult, but having access to these treatments profoundly changed my life, and for me it was absolutely worth doing the work.

Sources & Key Research

What next?